自体造血干细胞移植治疗进展性重症多发性硬化症。
Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis.
作者信息
Pandit Awadh Kishor, Prasad Kameshwar, Seth Tulika
机构信息
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Ann Indian Acad Neurol. 2015 Oct-Dec;18(4):459-63. doi: 10.4103/0972-2327.165482.
UNLABELLED
Multiple sclerosis (MS) is a chronic inflammatory disease of central nervous system (CNS), which is disabling and majorly involves younger population. Various available treatments in forms of immunomodulation are not very effective; however, stem cell transplantation seems to be promising in recent literature. The current case report is a novel evidence for autologous hematopoietic stem cell transplantation (HSCT) in progressive MS.
CASE SUMMARY
A 33 year old male with secondary progressive MS (SPMS), after being failed and/or intolerance to standard approved interferon (IFN) and mitoxantrone therapy, autologous HSCT was administered. At 2years of post-stem cell transplantation follow-up, he has remained stable with some improvement in functional status (Expanded Disability Status Scale (EDSS) reduced by 1.5), with no relapse, no treatment related complications, and no fresh magnetic resonance imaging (MRI) lesions.
CONCLUSION
Autologous stem cell transplantation may be beneficial in progressive forms of MS, but needs to be tested in well-designed randomized trial.
未标注
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性炎症性疾病，具有致残性，主要累及年轻人群。现有的各种免疫调节治疗方式效果都不太理想；然而，近期文献显示干细胞移植似乎颇具前景。本病例报告为自体造血干细胞移植（HSCT）治疗进展型MS提供了新的证据。
病例摘要
一名33岁的继发进展型MS（SPMS）男性患者，在对标准批准的干扰素（IFN）和米托蒽醌治疗无效和/或不耐受后，接受了自体HSCT。在干细胞移植后2年的随访中，他病情保持稳定，功能状态有所改善（扩展残疾状态量表（EDSS）降低了1.5），无复发，无治疗相关并发症，也没有新的磁共振成像（MRI）病变。
结论
自体干细胞移植可能对进展型MS有益，但需要在精心设计的随机试验中进行验证。
Zotero 插件